New developments in managing kidney cancer

Advances in diagnosis and treatment are changing how doctors manage renal cell carcinoma.

Renal cell carcinoma (RCC) is the most common kidney cancer. Each year, 435 000 patients are newly diagnosed worldwide.

Doctors use molecular subtyping to help with diagnostic classification. They also use cross sectional imaging like computed tomography or magnetic resonance imaging and selective biopsy.

For localized disease, nephrectomy is the standard of care. Partial nephrectomy is an option for smaller tumours. Ablation or stereotactic radiation works for selected patients.

Adjuvant pembrolizumab improves disease-free and overall survival in high risk clear cell RCC. In metastatic disease, immune checkpoint inhibitor based combinations extend overall survival.

Some patients experience a durable response. However, primary and secondary resistance remain a challenge. There is also a lack of predictive and prognostic biomarkers.

Key facts

  • 435 000 patients are newly diagnosed with renal cell carcinoma (RCC) each year.
  • Nephrectomy is the standard of care for localized disease.
  • Immune checkpoint inhibitor based combinations extend overall survival in metastatic disease.

All sections

Edition